- Home
- ANAB vs AUNA Comparison
ANAB vs AUNA Comparison
Compare ANAB & AUNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- AUNA
- Stock Information
- Founded
- ANAB 2005
- AUNA 1989
- Country
- ANAB United States
- AUNA Luxembourg
- Employees
- ANAB N/A
- AUNA N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- AUNA
- Sector
- ANAB Health Care
- AUNA
- Exchange
- ANAB Nasdaq
- AUNA NYSE
- Market Cap
- ANAB 600.4M
- AUNA 521.9M
- IPO Year
- ANAB 2017
- AUNA 2024
- Fundamental
- Price
- ANAB $22.27
- AUNA $7.11
- Analyst Decision
- ANAB Buy
- AUNA Strong Buy
- Analyst Count
- ANAB 11
- AUNA 4
- Target Price
- ANAB $54.64
- AUNA $13.40
- AVG Volume (30 Days)
- ANAB 623.5K
- AUNA 34.5K
- Earning Date
- ANAB 11-05-2024
- AUNA 11-19-2024
- Dividend Yield
- ANAB N/A
- AUNA N/A
- EPS Growth
- ANAB N/A
- AUNA N/A
- EPS
- ANAB N/A
- AUNA N/A
- Revenue
- ANAB $57,172,000.00
- AUNA $1,168,151,825.00
- Revenue This Year
- ANAB $207.49
- AUNA $18.29
- Revenue Next Year
- ANAB N/A
- AUNA $10.64
- P/E Ratio
- ANAB N/A
- AUNA N/A
- Revenue Growth
- ANAB 282.17
- AUNA 18.72
- 52 Week Low
- ANAB $13.36
- AUNA $6.17
- 52 Week High
- ANAB $41.31
- AUNA $10.85
- Technical
- Relative Strength Index (RSI)
- ANAB 42.41
- AUNA N/A
- Support Level
- ANAB $18.03
- AUNA N/A
- Resistance Level
- ANAB $22.94
- AUNA N/A
- Average True Range (ATR)
- ANAB 1.37
- AUNA 0.00
- MACD
- ANAB 0.45
- AUNA 0.00
- Stochastic Oscillator
- ANAB 86.18
- AUNA 0.00
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About AUNA AUNA S A
Auna SA is a healthcare provider. It operates hospitals and clinics in Mexico, Peru, and Colombia, and provides prepaid healthcare plans in Peru, and dental and vision plans in Mexico. Its network includes several healthcare network facilities, consisting of hospitals, outpatient, prevention, and wellness facilities. The company operates in the following segments; Oncosalud Peru, Healthcare services in Peru, Healthcare services in Colombia, and Healthcare services in Mexico. Key revenue is generated from Peru.